

2016 third-quarter and nine month financial information (1st January to 30st September 2016)

2016 3rd quarter results on track with the Bright2020 strategic plan roadmap

- Organic growth: +6.3%
- Recurring operating EBITDA margin: 15.9%
- Working capital requirements under control

Press release

Avignon, 8 November 2016 - Naturex, the global leader in speciality plant-based natural ingredients, releases its quarterly financial information for the third quarter and the first nine months of 2016.

Sound and well-managed organic growth

The Group continued and intensified its efforts in the 2016 third quarter on developing the priority areas defined under the Bright2020 strategic plan. These included building a higher value offering around innovation and the four key product categories as well as implementing a targeted customer approach and rationalising the number of product references.

2016 third quarter revenue rose in consequence to \bigcirc 8.4 million, displaying organic growth 6.3% like-for-like and at constant exchange rates¹, compared with last year's third quarter.

For the first nine months, revenue rose to €306.4 million, up from €297.0 million for the same period in 2015, representing organic growth of 5.7% like-for-like and at constant exchange rates

(€000's) IFRS (Unaudited data)	3 nd quarter 2016	3 nd quarter 2015		Change (%)	Organic growth ¹ (%)
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales ²
My Natural Food	51,496	47,193	52.3%	+9.1%	+11.1%
My Natural Selfcare	33,511	32,188	34.1%	+4.1%	+4.5%
Other activities*	13,398	14,941	13.6%	-10.3%	-5.3%
TOTAL	98,404	94,321	100.0%	+4.3%	+6.3%

Positive trends for both strategic platforms

* of which Q3 2015 krill toll manufacturing sales: €764,000

My Natural Food registered 11.1% in organic growth for the 2016 third quarter with a favourable comparison base in 2015, reaching revenue of €51.5 million. This performance reflected the improved

¹ Organic growth: Growth at constant exchange rates and like-for-like (excluding acquisitions, disposals or discontinued operations, businesses...) ²Krill toll manufacturing sales: Business transferred at the end of 2015 to the JV with Aker BioMarine, with the disposal of Naturex's stake announced in March 2016 and, as of this date, completed.



NATUREX

product mix built around key product categories, underpinned by continuing very positive trends for natural ingredients, particularly for speciality fruit and vegetables and colours.

For the first nine months revenue reached €159.4 million, up 6.9% like-for-like from the same period in 2015.

My Natural Selfcare had organic growth of 4.5% in the 2016 third quarter from a high comparison base in 2015, with revenue of €33.5 million. This performance confirms the growing momentum for the clinically-substantiated phytoactives product range and also the effects of Naturex's traceability and quality control commitments for its plant extracts in a market of continuing volatility and subject to numerous regulatory requirements.

For the first-nine months, revenue rose to €104.6 million, gaining 7.6% like-for-like from the same period in 2015.

Other activities had revenue of ≤ 13.4 million in the 2016 third quarter, down 5.3% like-for-like and at constant exchange rates. Revenue for the first nine months amounted to ≤ 42.4 million compared to ≤ 49.9 million for the same period in 2015, reflecting mainly the discontinuation of the krill toll manufacturing.

(€000's) IFRS (Unaudited data)	3 nd quarter 2016	3 nd quarter 2015	Revenue mix (%)	Change (%)	Organic growth %
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales
Europe/Africa/Middle East*	33,639	33,943	34.2%	-0.9%	+4.3%
North America,	42,710	42,106	43.4%	+1.4%	+1.6%
Latin America	8,198	7,669	8.3%	+6.9%	+7.3%
Asia/Pacific	13,857	10,604	14.1%	+30.7%	+31.0%
TOTAL	98,404	94,321	100.0%	+4.3%	+6.3%

Visible benefits from simplification across all regions

* of which Q3 2015 krill toll manufacturing sales: €764,000

The **Europe/Africa/Middle East region** had revenue of 33.6 million in the 2016 third quarter with organic growth of 4.3%. This increase reflects the gradual upgrading of the product portfolio by shifting to key categories whereas simplification and rationalisation measures actively pursued will continue to weigh upon the region's business performance over the coming months.

For the first nine months, revenue amounted to €111.4 million, up 5.7% like for like from the same period in 2015.

North America had revenue of 42.7 million in the 2016 third quarter with organic growth of 1.6% compared to the same period in 2015. Measures for reducing complexity and tension within the supply chain were intensified with the goal of providing optimal service to the targeted customer base. The strong contribution from Food & Beverage is masked by the volatility of Nutrition & Health business with the nutraceutical market going through a period of transition according to regulatory requirements.

For the first nine months of 2016, revenue amounted to €133.6 million, remaining largely steady (-0.8%) in relation to a high comparison base in 2015.

The Latin America and Asia-Pacific regions, energised by the new organisation, benefited from positive trends in their respective markets. On that basis, in the 2016 third quarter, the Latin American





region had €8.2 million in revenue, up 7.3% at constant exchange rates and the **Asia-Pacific** region €13.9 million in revenue with organic growth of 31.0%.

These two emerging regions had combined sales of €61.4 million in 2016, representing 20.0% of total Group revenue.

A steadily improving performance

Recurring operating EBITDA ³ amounted to €15.6 million in the 2016 third quarter, representing a margin of 15.9% and reflecting measures designed to make better use of production capacity and improve productivity. For the first nine months, recurring operating EBITDA in consequence amounted to €48.8 million.

Working Capital Requirements amounted to €196.3 million at 30 September 2016, up from €186.1 million at 30 June 2016. This increase is largely a consequence of the inventory categorisation process linked to measures taken to rationalise product references and build a higher value product range. The Group is also continuing to actively manage customer credit risk and supplier payment terms.

"The 2016 third quarter's good performance is on track with the roadmap of our Bright 2020 strategic plan. Our commitments in terms of rigour and discipline aimed at simplifying and energising our operating model to achieve strong and lasting growth by 2020 are starting to produce benefits. In these first nine months of 2016, we were successful in combining the rationalisation of our product portfolio and shift to a higher value offering around strategic product categories by implementing a regional commercial governance model that is now complete. We have also focused on increasing efficiencies at our industrial sites and optimising costs in order to generate the operating drivers necessary to improve our profitability", commented Olivier Rigaud, Chief Executive Officer and Director of Naturex.

"With the nutraceutical market going through period of transition, creating volatility in the short-term and impacting performances of some of our customers that have already confirmed postponements of orders until 2017, expectations for the 2016 fourth-quarter are in consequence less favourable. In the upcoming months, particular efforts will be devoted to ramping up our investments in research and innovation but also further streamlining our product references and structuring and optimising our industrial capacities."

You can receive all financial information of Naturex free of charge by signing up at: www.naturex.com

³ To better reflect the annual performance without the impact of inventory management measures that were not generated over the period, Naturex adopted a new alternative performance indicator. The destruction of stock and inventory provisions for more than two years are now eliminated from EBITDA under the term of recurring operational EBITDA. The previously used indicator of Recurring EBITDA took into account only the restatement of amortisation, depreciation and impairment of tangible or intangible fixed assets.





CONFERENCE CALL

A conference call will be held on Wednesday 9 November at 10:00 a.m. (French time); A webcast of the presentation will be available live and by retransmission from the following link:

Access to the webcast from a computer

To access the live or replay version of this webcast from a computer, click on: <u>http://edge.media-server.com/m/p/v7gu63pj</u>

Access to the webcast from a mobile device - QR code

To access the live or replay version of this webcast from mobile phones or tablet devices using iOS and android operating systems:



Upcoming events

- Actionaria tradeshow (Paris)

Financial schedule

- Revenue FY 2016
- 2016 annual results

18-19 November 2016

6 February 2017 29 March 2017





About Naturex

Naturex sources, manufactures and markets natural speciality ingredients for the food, health and cosmetic industries. As the Natural Maker, the company actively supports the global shift from synthetic to natural through an offer built on two main focus areas: My Natural Food and My Natural Selfcare. Naturex's portfolio includes colours, antioxidants, speciality fruits & vegetables, phytoactives, and numerous other plant-based natural ingredients, designed to create healthy, authentic and effective products.

The Group's strong commitment to quality, sustainability, continuous innovation process, and the talent of its people are at the heart of its success.

Headquartered in Avignon, France, Naturex has experienced steadily-increasing growth throughout the last 20 years. The group posted €397.8 million in sales in 2015 and employs 1,700 people worldwide. The Group is listed on Euronext Paris, Compartment B – Index: Euronext Next 150, Enternext CAC PEA-PME 150, CAC Small & Mid, CAC Small, Gaïa - Ticker: NRX - Reuters: NATU.PA - Bloomberg: NRX:FP - DR SYMBOL: NTUXY

NATUREX, From Nature to You

Contacts

Carole Alexandre Investor Relations Tel.: +33 (0)4 90 23 78 28 c.alexandre@naturex.com Anne Catherine Bonjour Actus Finance Press Relations Tel.: +33 (0)1 53 67 36 93 acbonjour@actus.fr



NATUREX

APPENDIX

- Nine-month revenue highlights by business and region

(€000's) IFRS (Unaudited data)	FY 2016	FY 2015	Change (%)	Organic growth %	
(,			Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales	
1 st quarter	104,404	98,602	+5.9%	+6.3%	
2 nd quarter	103,637	104,047	-0.4%	+4.4%	
H1	208,041	202,650	+2.7%	+5.3%	
3 nd quarter	98,404	94,321	+4.3%	+6.3%	
9 months	306,445	296,971	+3.2%	+5.7%	

(€000's) IFRS (Unaudited data)	9 months 2016	9 months 2015	Revenue mix (%)	Change (%)	Organic growth %
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales
My Natural Food	159,359	150,039	52.0%	+6.2%	+6.9%
My Natural Selfcare	104,638	97,069	34.1%	+7.8%	+7.6%
Other activities*	42,448	49,863	13.9%	-14.9%	-2.7%
TOTAL	306,445	296,971	100.0%	+3.2%	+5.7%

* of which 2015 nine-month krill toll manufacturing sales: €5,956,000

(€000's) IFRS (Unaudited data)	9 months 2016	9 months 2015	Revenue mix (%)	Change (%)	Organic growth %
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales
Europe/Africa/Middle East*	111,437	112,751	36.4%	-1.2%	+5.7%
North America,	133,632	133,847	43.6%	-0.2%	-0.8%
Latin America	22,241	18,281	7.3%	+21.7%	+21.6%
Asia/Pacific	39,135	32,092	12.8%	+21.9%	+23.6%
TOTAL	306,445	296,971	100.0%	+3.2%	+5.7%

* of which 2015 nine-month krill toll manufacturing sales: €5,956,000





- Quarterly revenue mix by business

1 st quarter							
(€000's) IFRS (Unaudited data)	1 st quarter 2016	1 st quarter 2015	Revenue mix (%)	Change (%)	Organic growth %		
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales		
My Natural Food	53,083	50,049	50.8%	+6.1%	+3.2%		
My Natural Selfcare	37,029	31,452	35.5%	+17.7%	+14.7%		
Other activities*	14,291	17,102	13.7%	-16.4%	-1.2%		
TOTAL	104,404	98,602	100.0%	+5.9%	+6.3%		

* of which Q1 2015 krill toll manufacturing sales: €2,789,000.

2 nd quarter						
(€000's) IFRS (Unaudited data)	2 nd quarter 2016	2 nd quarter 2015	Revenue mix (%)	Change (%)	Organic growth %	
(Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales	
My Natural Food	54,779	52,797	52.9%	+3.8%	+6.5%	
My Natural Selfcare	34,099	33,430	32.9%	+2.0%	+3.9%	
Other activities*	14,759	17,820	14.2%	-17.2%	-1.7%	
TOTAL	103,637	104,047	100.0%	-0.4%	+4.4%	

* of which Q2 2015 krill toll manufacturing sales: €2,403,000

3 rd quarter							
(€000's) IFRS (Unaudited data)	3 nd quarter 2016	3 nd quarter 2015	Revenue mix (%)	Change (%)	Organic growth %		
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales		
My Natural Food	51,496	47,193	52.3%	+9.1%	+11.1%		
My Natural Selfcare	33,511	32,188	34.1%	+4.1%	+4.5%		
Other activities*	13,398	14,941	13.6%	-10.3%	-5.3%		
TOTAL	98,404	94,321	100.0%	+4.3%	+6.3%		

* of which Q3 2015 krill toll manufacturing sales: €764,000



NATUREX

- Quarterly revenue mix by region

1 st quarter							
(€000's) IFRS (Unaudited data)	1 st quarter 2016	1 st quarter 2015	Revenue mix (%)	Change (%)	Organic growth %		
				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales		
Europe/Africa/Middle East*	39,408	38,875	37.7%	+1.4%	+9.3%		
North America,	45,101	45,517	43.2%	-0.9%	-6.0%		
Latin America	6,339	4,162	6.1%	+52.3%	+46.1%		
Asia/Pacific	13,556	10,047	13.0%	+34.9%	+34.9%		
TOTAL	104,404	98,602	100.0%	+5.9%	+6.3%		

* of which Q1 2015 krill toll manufacturing sales: €2,789,000.

2 nd quarter							
(€000's) IFRS (Unaudited data)	2 nd quarter 2016	2 nd quarter 2015	Revenue mix (%)	Change (%)	Organic growth %		
`				Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales		
Europe/Africa/Middle East*	38,389	39,933	37.0%	-3.9%	+3.4%		
North America,	45,822	46,224	44.2%	-0.9%	+2.1%		
Latin America	7,705	6,450	7.4%	+19.4%	+22.9%		
Asia/Pacific	11,722	11,440	11.3%	+2.5%	+6.9%		
TOTAL	103,637	104,047	100.0%	-0.4%	+4.4%		

* of which Q2 2015 krill toll manufacturing sales: €2,403,000

3 nd quarter							
(€000's) IFRS (Unaudited data)	3 nd quarter 2016	3 nd quarter 2015	Revenue mix (%)	Change (%)	Organic growth %		
			Current exchange rates	Constant exchange rates excl. krill toll manufacturing sales			
Europe/Africa/Middle East*	33,639	33,943	34.2%	-0.9%	+4.3%		
North America,	42,710	42,106	43.4%	+1.4%	+1.6%		
Latin America	8,198	7,669	8.3%	+6.9%	+7.3%		
Asia/Pacific	13,857	10,604	14.1%	+30.7%	+31.0%		
TOTAL	98,404	94,321	100.0%	+4.3%	+6.3%		

* of which Q3 2015 krill toll manufacturing sales: €764,000

